These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10547171)

  • 1. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.
    Lee M; Kemp JA; Canning A; Egan C; Tataronis G; Farraye FA
    Arch Intern Med; 1999 Oct; 159(19):2312-6. PubMed ID: 10547171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helicobacter pylori eradication in dyspeptic primary care patients: a randomized controlled trial of a pharmacy intervention.
    Stevens VJ; Shneidman RJ; Johnson RE; Boles M; Steele PE; Lee NL
    West J Med; 2002 Mar; 176(2):92-6. PubMed ID: 11897728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of the active pharmaceutical ingredient bismuth subsalicylate.
    Svensson Grape E; Rooth V; Nero M; Willhammar T; Inge AK
    Nat Commun; 2022 Apr; 13(1):1984. PubMed ID: 35418171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the side effects and resistance in H. pylori treatment: a discussion on minocycline versus tetracycline therapy.
    Kurokawa T; Kurokawa T
    J Gastroenterol; 2024 Apr; 59(4):357. PubMed ID: 38416245
    [No Abstract]   [Full Text] [Related]  

  • 5. Helicobacter pylori treatment knowledge, access and barriers: A cross-sectional study.
    Bailey KS; Brown HE; Lekic V; Pradeep K; Merchant JL; Harris RB
    Helicobacter; 2023 Apr; 28(2):e12954. PubMed ID: 36748455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community prevalence of
    Lee YJ; Ssekalo I; Kazungu R; Blackwell TS; Muwereza P; Wu Y; Sáenz JB
    Heliyon; 2022 Dec; 8(12):e12612. PubMed ID: 36593846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a WeChat-based mini-app as a patient reminder in Helicobacter pylori eradication: a prospective multi-center randomized controlled study.
    Sun K; Chen Y; Wang Z; Liu Y; Pan Y; Mao X; Xu L; Jin C; Chen M; Yu C; Li L
    BMC Gastroenterol; 2022 Dec; 22(1):520. PubMed ID: 36522612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practice guidelines for the management of
    Alsohaibani F; Peedikayil M; Alshahrani A; Somily A; Alsulaiman R; Azzam N; Almadi M
    Saudi J Gastroenterol; 2023; 29(6):326-346. PubMed ID: 36204804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line
    Losurdo G; Lacavalla I; Russo F; Riezzo G; Brescia IV; Rendina M; Ierardi E; Di Leo A
    Antibiotics (Basel); 2022 Jan; 11(1):. PubMed ID: 35052955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helicobacter pylori Management Is Associated with Predominantly Negative Patient Experiences: Results from a Focused Qualitative Analysis.
    Shah SC; Bonnet K; Schulte R; Peek RM; Schlundt D; Roumie CL
    Dig Dis Sci; 2022 Sep; 67(9):4387-4394. PubMed ID: 35034240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for
    Kang S; Kim Y; Ahn JY; Jung HY; Kim N; Na HK; Lee JH; Jung KW; Kim DH; Choi KD; Song HJ; Lee GH
    Antibiotics (Basel); 2021 Feb; 10(2):. PubMed ID: 33669969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review.
    Shah SC; Iyer PG; Moss SF
    Gastroenterology; 2021 Apr; 160(5):1831-1841. PubMed ID: 33524402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent Helicobacter pylori Infection: An Insight to the Limitations of Current Clinical Practice.
    Liyen Cartelle A; Uy PP; Koehler TE; Yap JEL
    Cureus; 2020 Dec; 12(12):e12309. PubMed ID: 33520508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telephone-Based Reeducation of Drug Administration for
    Zhao Y; Ren M; Wang X; Lu G; Lu X; Zhang D; He S
    Gastroenterol Res Pract; 2020; 2020():8972473. PubMed ID: 32802048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study.
    Gebeyehu E; Nigatu D; Engidawork E
    PLoS One; 2019; 14(11):e0225585. PubMed ID: 31756217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical background factors affecting outcomes of
    Yokota N; Ae R; Amenomori M; Kitagawa K; Nakamura T; Yokota T; Masato K; Sasahara T; Matsubara Y; Kosami K; Nakamura Y
    J Gen Fam Med; 2019 Jul; 20(4):139-145. PubMed ID: 31312580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vonoprazan and
    Abadi ATB; Ierardi E
    Front Pharmacol; 2019; 10():316. PubMed ID: 31024299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between  daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled  trial.
    Shahbazi S; Vahdat Shariatpanahi Z
    Indian J Gastroenterol; 2018 Nov; 37(6):550-554. PubMed ID: 30635887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive molecular analysis of
    Ierardi E; Giorgio F; Iannone A; Losurdo G; Principi M; Barone M; Pisani A; Di Leo A
    World J Gastroenterol; 2017 Apr; 23(14):2453-2458. PubMed ID: 28465629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
    Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
    BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.